REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients (Resonance)
Status: Recruiting
Conditions: Pericarditis
Location:
Alaska Heart & Vascular InstituteBarnes-Jewish Hospital/Washington University
Brigham and Women's Hospital
Carnegie Mellon University
Cedars-Sinai Medical Center
Children's National Hospital- Washington D.C.
Cincinnati Children's Hospital Medical Center
Cleveland Clinic
Detroit Medical Center
Houston Methodist Hospital
Johns Hopkins University
Lender Research Center at the Christ Hospital
Massachusetts General Hospital
Mayo Clinic in Rochester
Midwest Cardiovascular Research Foundation
Minneapolis Heart Institute Foundation
NYU Langone Health
Northwell Health - Lenox Hill Hospital
Northwestern University Medicine
Pima Heart and Vascular
Scripps Health
Seattle Children's Hospital
Swedish Medical Center - Cherry Hill
TKL Research Inc.
University of California - San Diego
University of Texas Southwestern
University of Utah
University of Vermont Medical Center
Virginia Commonwealth University
City/State:
Anchorage, Alaska
Tucson, Arizona
La Jolla, California
San Diego
Davenport, Iowa
Baltimore, Maryland
Boston, Massachusetts
Minneapolis, Minnesota
Rochester, Minnesota
Saint Louis, Missouri
Fair Lawn, New Jersey
New York, New York
Cincinnati, Ohio
Cleveland, Ohio
Pittsburgh, Pennsylvania
Houston, Texas
Burlington, Vermont
Richmond, Virginia
Seattle, Washington
Los Angeles, California
Washington, D.C.
Chicago, Illinois
Detroit, Michigan
Dallas, Texas
Salt Lake City, Utah
Contact Information:
JoAnn Clair, PhD
781 431 9100
[email protected]
Brief Summary:
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
